Compounds > WWL113
Page last updated: 2024-08-03 07:17:46

WWL113

Description

WWL113 : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID17759482
CHEMBL ID4303156
CHEBI ID188795

Synonyms (23)

Synonym
sr-02000000418
SR-02000000418-1
ethyl 4'-((methyl(3-(pyridin-4-yl)benzyl)carbamoyl)oxy)-[1,1'-biphenyl]-4-carboxylate
wwl113
947669-86-5
AKOS025147340
wwl 113
4'-[[[methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-[1,1'-biphenyl]-4-carboxylic acid ethyl ester
wwl-113
wwl113, >=98% (hplc)
NCGC00384183-06
HY-110148
AS-16603
SB17008
ethyl 4-[4-[methyl-[(3-pyridin-4-ylphenyl)methyl]carbamoyl]oxyphenyl]benzoate
HMS3872M13
NCGC00384183-07
CHEMBL4303156
CS-0033006
A900141
[1,1'-biphenyl]-4-carboxylic acid, 4'-[[[methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-, ethyl ester
XMB66986
CHEBI:188795

Drug Classes (1)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
GVesicular stomatitis virusPotency0.9522AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency6.7412AID1645840
Interferon betaHomo sapiens (human)Potency0.9522AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.9522AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.9522AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.9522AID1645842

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
ISSN: 1552-454X		A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2022Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1
ISSN: 1475-6374

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
bay h 4502
0
biphenyls;
imidazoles		00low000000
candesartan cilexetil
0
biphenyls00low000000
4-biphenylylacetic acid
0
biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug00low000000
fenbufen
0
4-oxo monocarboxylic acid;
biphenyls		non-steroidal anti-inflammatory drug00low000000
3,3'-dichlorobenzidine
0
biphenyls;
monochlorobenzenes;
organochlorine compound		00low000000
3,3'-diaminobenzidine
0
biphenyls;
substituted aniline		histological dye00low000000
diphenyl
0
aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative		00low000000
benzidine
0
biphenyls;
substituted aniline		carcinogenic agent00low000000
4-nitrobiphenyl
0
biphenyls00low000000
dianisidine
0
biphenyls00low000000
2-tolidine
0
biphenyls00low000000
n,n'-diacetylbenzidine
0
biphenyls00low000000
2-amino-4-phenylphenol
0
biphenyls00low000000
4-acetylaminobiphenyl
0
biphenyls00low000000
4-biphenylylacetic acid ethyl ester
0
biphenyls00low000000
brequinar
0
biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor		00low000000
tasosartan
0
biphenyls00low000000
telmisartan
0
benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic		00low000000
clobuzarit
0
biphenyls;
organochlorine compound		00low000000
magnolol
0
biphenyls00low000000
honokiol
0
biphenyls00low000000
bitertanol
0
aromatic ether;
biphenyls;
secondary alcohol;
triazoles		00low000000
isodiospyrin
0
biphenyls00low000000
difenpiramide
0
biphenyls;
monocarboxylic acid amide;
pyridines		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		00low000000
2-(4-phenylphenoxy)propanoic acid
0
biphenyls00low000000
4-hydroxy-2',4',6'-trichlorobiphenyl
0
biphenyls;
trichlorobenzene		00low000000
4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl
0
biphenyls;
tetrachlorobenzene		00low000000
dityrosine
0
biphenyls;
non-proteinogenic alpha-amino acid;
tyrosine derivative		biomarker00low000000
4,4'-bis(methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl
0
biphenyls;
dichlorobenzene;
sulfone		00low000000
nitroflurbiprofen
0
biphenyls;
carboxylic ester;
nitrate ester;
organofluorine compound		cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector;
non-steroidal anti-inflammatory drug;
vasodilator agent		00low000000
olmesartan medoxomil
0
biphenyls00low000000
4'-hydroxyflurbiprofen
0
biphenyls00low000000
dehydrodieugenol
0
biphenyls00low000000
bifeprunox
0
biphenyls00low000000
2-chloro-n-(4-chlorobiphenyl-2-yl)nicotinamide
0
anilide fungicide;
biphenyls;
monochlorobenzenes;
pyridinecarboxamide		antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
environmental contaminant;
xenobiotic		00low000000
aucuparin
0
biphenyls00low000000
2-[(3,4-dimethoxyphenyl)methyl]-5-[4-(4-methoxyphenyl)phenyl]-1,3,4-oxadiazole
0
biphenyls00low000000
2-(2,5-dimethoxyphenyl)-5-[4-(4-methoxyphenyl)phenyl]-1,3,4-oxadiazole
0
biphenyls00low000000
(2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide)
0
biphenyls00low000000
4-phenylbenzoic acid (propan-2-ylideneamino) ester
0
biphenyls00low000000
N-[[(6-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-4-phenylbenzamide
0
biphenyls00low000000
4-phenyl-N-(2-propyl-5-tetrazolyl)benzamide
0
biphenyls00low000000
2-[(1-methyl-5-tetrazolyl)thio]-N-(2-phenylphenyl)acetamide
0
biphenyls00low000000
3-phenyl-5-(2-phenylphenyl)-1,2,4-oxadiazole
0
biphenyls00low000000
N-[[methyl-(phenylmethyl)amino]-sulfanylidenemethyl]-4-phenylbenzamide
0
biphenyls00low000000
N-[4-[4-(ethylsulfonylamino)-3-methoxyphenyl]-2-methoxyphenyl]ethanesulfonamide
0
biphenyls00low000000
urb 597
0
biphenyls00low000000
3-(4-phenylphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine
0
biphenyls00low000000
ac 55649
0
biphenyls;
carboxybiphenyl		00low000000
1-[3-(4-phenylphenoxy)propyl]-1,2,4-triazole
0
biphenyls00low000000
N-[2-(2-phenylphenoxy)ethyl]-2-furancarboxamide
0
biphenyls00low000000
2-(2-phenylanilino)-N-(phenylmethyl)acetamide
0
biphenyls00low000000
4-(2-fluorophenyl)-N-(2-methylbut-3-yn-2-yl)benzamide
0
biphenyls00low000000
5-oxo-3-(4-phenylphenyl)-2H-furan-4-carbonitrile
0
biphenyls00low000000
N-([biphenyl]-2-yl)-3-cyclopentylpropanamide
0
biphenyls;
cyclopentanes;
secondary carboxamide		00low000000
1-(4-morpholinyl)-2-(4-phenylphenoxy)-1-propanone
0
biphenyls00low000000
2-(4-morpholinyl)-N-(2-phenylphenyl)propanamide
0
biphenyls00low000000
4-[4-[2-hydroxy-3-(4-morpholinyl)propoxy]phenyl]benzonitrile
0
biphenyls;
nitrile		00low000000
3-[4-[(2-hydroxy-5-phenylphenyl)methyl]-1-piperazinyl]propanenitrile
0
biphenyls00low000000
N-(2-methoxyethyl)-4-[4-(2-methoxyethylsulfamoyl)phenyl]benzenesulfonamide
0
biphenyls00low000000
2-phenylbutanoic acid [2-oxo-2-(2-phenylanilino)ethyl] ester
0
biphenyls00low000000
2-(4-benzoyl-1-piperazinyl)-N-(2-phenylphenyl)propanamide
0
biphenyls00low000000
fexaramine
0
biphenyls00low000000
alx 5407
0
biphenyls00low000000
bay 12-9566
0
biphenyls;
organochlorine compound		00low000000
sacubitril
0
biphenyls00low000000
biphenyl-indanone a
0
biphenyls00low000000
fimasartan
0
biphenyls00low000000
2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid
0
biphenyls;
organobromine compound		00low000000
l-161982
0
biphenyls00low000000
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
0
1,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor00low000000
abt-737
0
aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor		00low000000
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide
0
biphenyls00low000000
ly2183240
0
biphenyls00low000000
fluxapyroxad
0
anilide fungicide;
aromatic amide;
biphenyls;
pyrazoles;
trifluorobenzene		antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor		00low000000
(3R,3aS,7R,7aS)-3-[4-[4-(dimethylamino)phenyl]-2-fluorophenyl]-7-methyl-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one
0
biphenyls00low000000
3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide
0
biphenyls00low000000
lde225
0
aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist		00low000000
N-[3-(3-chlorophenyl)phenyl]-1-(3-isoxazolylmethyl)-4-piperidinecarboxamide
0
biphenyls;
organochlorine compound		00low000000
N-[3-(3-chlorophenyl)phenyl]-1-(3-oxolanylmethyl)-4-piperidinecarboxamide
0
biphenyls;
organochlorine compound		00low000000
4-(4-acetyloxyphenyl)benzoic acid [2-[[2-(2-chloroanilino)-2-oxoethyl]-methylamino]-2-oxoethyl] ester
0
biphenyls00low000000
N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide
0
benzamides;
biphenyls;
cyclopropanes;
dicarboxylic acid diamide		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor00low000000
tak-875
0
biphenyls00low000000
bms-790052
0
biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor		00low000000
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol
0
biphenyls00low000000
4-[(1-methyl-5-tetrazolyl)thio]-5-(4-phenylphenyl)thieno[2,3-d]pyrimidine
0
biphenyls;
thienopyrimidine		00low000000
ml228 probe
0
1,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound		hypoxia-inducible factor pathway activator00low000000
a 769662
0
biphenyls00low000000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Congenital Zika Syndrome0
1
202020204.0medium000010
Disease Models, Animal0
1
202020204.0medium000010
Malaria, Falciparum0
1
2014201410.0medium000010
Plasmodium falciparum Malaria0
1
2014201410.0medium000010
Zika Virus Infection0
1
202020204.0medium000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019